you are a specialist
a dermatologist or
general practitioner

Contact us   

MELAPRED test overview

The risk of developing cutaneous melanoma is associated with clinical risk factors (skin and eye colour, phototype, number of moles etc.) and genetic factors (predisposition genes or protective genes against disease).
 MELAPRED is a test that simultaneously integrates both genetic factors and clinical risk factors, which thanks to a specific algorithm enables the calculation of a melanoma risk score de mélanome (between 0 and 100) for the patient.
MELAPRED is the result of 15 years research and has the following features :
  • Specific algorithm that integrates known clinical and genetic risk factors
  • Developed and validated on more than 6000 individuals (patient cohorts and healthy testing)
  • APHP (Assistance Publique Hôpitaux de Paris) patent
  • CE marking and hearing by the ANSM

The MELAPRED test enables :

  • Earlier screening which ensures a better prognosis
  • Personalized follow-up care of your patients
  • Specific surveillance of patients identified as high risk by the test
  • Patient education and avoidance of risk behaviours
  • Authoritative advice

Performance

courbe roc variables génétiques
Model only takes into account the genetic variables (French cohort –black line, Spanish cohort – red dotted line)
AUC French (genetic) = 0.67
AUC Spanish (genetic) = 0.65
The genetic score replicates very well
courbe roc variables génétiques + cliniques
Model takes into account the clinical and genetic variables on the French cohort (clinical + genetic models – black lines, clinical model – red dotted line)

AUC (clinical + genetic) = 0.75
The model is significantly improved

Pilot study (2014)

  • 261 patients, 23 research physicians
  • 50% patients in Paris : CHU Bichat/Saint Louis + independent dermatologists (Coordination Nadem Soufir)
  • 50% patients in Reims : CHU Reims + dermatologists + general practitioners (Coordination Florent Grange)
  • Test proposal + informed consent
Pilot study results
- 162 high-risk patients (64%) of which 30 % of patients with no phenotype risk factors, were clearly identifiable
- 51 patients with a number of moles < 50
- 59 patients with phototype 3 or 4

MELAPRED Survey (n = 163)

94%
The test is useful
69%
The test will have an impact on my behaviour
94%
I will recommend the test to those close to me
64%
The test was not a cause for concern
60%
I would be willing to pay for the Melapred test

Patient programme

Step 1
Consultation, information given to the patient, test prescription, and patient consent. After an examination, the patient’s clinical data is recorded on a specific form.
Step 2
The doctor collects an oral DNA sample from the kit supplied by Genepredict.
Step 3
The sample + data sheet + patient agreement are sent by the patient to Genepredict in a pre-addressed and pre-stamped envelope.
Step 4
Genepredict organizes genetic analyses, processes the clinical data, and then sends the result by courrier to the patient’s doctor.
Step 5
Consultation: the results of the test are given to the patient within 15 days with explanations and recommendations.

And the price?

The Melapred test costs 149 euros. It is not reimbursed by social security.

Download area

haut